Aurelian-Emil Ranetti
About
In The Last Decade
Aurelian-Emil Ranetti
18 papers receiving 301 citations
Peers
Comparison fields: 5 of 88
- Endocrinology, Diabetes and Metabolism 166
- Molecular Biology 100
- Surgery 97
- Epidemiology 59
- Pharmacology 29
Countries citing papers authored by Aurelian-Emil Ranetti
This map shows the geographic impact of Aurelian-Emil Ranetti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aurelian-Emil Ranetti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aurelian-Emil Ranetti more than expected).
Fields of papers citing papers by Aurelian-Emil Ranetti
This network shows the impact of papers produced by Aurelian-Emil Ranetti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aurelian-Emil Ranetti. The network helps show where Aurelian-Emil Ranetti may publish in the future.
Co-authorship network of co-authors of Aurelian-Emil Ranetti
This figure shows the co-authorship network connecting the top 25 collaborators of Aurelian-Emil Ranetti. A scholar is included among the top collaborators of Aurelian-Emil Ranetti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aurelian-Emil Ranetti. Aurelian-Emil Ranetti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 0 | |
| 3 | 1 | |
| 4 | 0 | |
| 5 | 0 | |
| 6 | 4 | |
| 7 | 1 | |
| 8 | 1 | |
| 9 | 10 | |
| 10 | 3 | |
| 11 | A Randomized, Double-Blind, Phase 3 Trial of Dapagliflozin Add-on to Saxagliptin plus Metformin in Type 2 Diabetes | 2 |
| 12 | 0 | |
| 13 | 125 | |
| 14 | URSODEOXYCHOLIC ACID EFFECTS ON CYSTIC FIBROSIS LIVER DISEASE | 3 |
| 15 | FORMULATION AND EVALUATION OF IN VITRO RELEASE KINETICS OF NA 3 CADTPA DECORPORATION AGENT EMBEDDED IN MICROEMULSION-BASED GEL FORMULATION FOR TOPICAL DELIVERY | 43 |
| 16 | 1 | |
| 17 | 32 | |
| 18 | Effect of diet and omega-3 fatty acids in NAFLD. | 13 |
| 19 | BENEFICIAL EFFECTS OF OMEGA-3 FATTY ACIDS IN NONALCOHOLIC FATTY LIVER DISEASE, IN CHILDHOOD OBESITY | 4 |
| 20 | Heart failure and dilated cardiomyopathy associated with severe longstanding untreated hypothyroidism. | 12 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.